Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis

Journal of Investigative Medicine

Volumn 59, Issue 2, 2011, Pages 246-258

  Swan, Joshua T ^a   Riche, Daniel M ^b   Riche, Krista D ^c   Majithia, Vikas ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c Department of Pathology   (United States)

Author keywords

Class V lupus nephritis; Glomerulonephritis; Membranous lupus nephritis; Meta analysis; Systemic lupus erythematosus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIMALARIAL AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; STEROID; TACROLIMUS; CREATININE; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID;

CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MEMBRANOUS GLOMERULONEPHRITIS; MEMBRANOUS LUPUS NEPHRITIS; META ANALYSIS; MONOTHERAPY; PLASMAPHERESIS; PROTEINURIA; RELAPSE; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; AGRANULOCYTOSIS; ALOPECIA; AMENORRHEA; ANGIONEUROTIC EDEMA; ARTICLE; AVASCULAR NECROSIS; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DYSPEPSIA; EMBASE; GINGIVA HYPERPLASIA; HAIR LOSS; HIP DISEASE; HYPERTRANSAMINASEMIA; HYPERTRICHOSIS; LEUKOPENIA; LUNG TUBERCULOSIS; MEDLINE; MENSTRUAL IRREGULARITY; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SIDE EFFECT; TREATMENT OUTCOME; TREMOR;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; PUBLICATION BIAS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 85008244080     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318204c965     Document Type: Review

References (37)

1. Austin HA, Illei GG. Membranous lupus nephritis. Lupus. 2005;14:65-71. (Pubitemid 40216071)
2. Buhaescu I, Covik A, Deray G. Treatment of proliferative lupus nephritis Y a critical approach. Semin Arthritis Rheum. 2007;36: 224-237. (Pubitemid 46178520)
3. Mercadal L, Montcel ST, Nochy D, et al. Factors affecting outcome and prognosis in membranous lupus nephritis. Nephrol Dial Transplant. 2002;17:1771-1778. (Pubitemid 35174288)
4. Sloan RP, Schwartz MM, Korbet SM, et al. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. J Am Soc Nephrol. 1996;7:299-305. (Pubitemid 26092479)
5. Austin HA, Illei GG, Braun MJ, et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol. 2009;20:901-911.
6. Borba EF, Guedes LK, Christmann RB, et al. Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol Int. 2006;26:1078-1083. (Pubitemid 44450841)
7. Chan TM, Li FK, Hao WK, et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus. 1999;8:545-551. (Pubitemid 29452568)
8. Chan TM, Li FK, Wong RW, et al. Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephrology. 1995;71:321-327.
9. Dixit MP, Bracamonte E, Dixit N. Intravenous cyclophosphamide-resistant systemic lupus erythematosus in Arizona. Pediatr Nephrol. 2004;19:738-743. (Pubitemid 38931155)
10. Faedda R, Palomba D, Sata A, et al. Immunosuppressive treatment of the glomerulonephritis in systemic lupus. Clin Nephrol. 1995;44: 367-375. (Pubitemid 26002815)
11. Grcevska L, Polenakovic M. Mycophenolate mofetil in the treatment of glomerular diseases. Prilozi. 2007;28:57-68.
12. Houssaini T, Benabdallah L, Arrayhani M, et al. Initial presentation and course of lupus membranous glomerulonephritis. Presse Med. 2008;37:559-563.
13. Hu W, Liu Z, Shen S, et al. Cyclosporine A in treatment of membranous lupus nephropathy. Chin Med J. 2003;116:1827-1830. (Pubitemid 38159879)
14. Kapitsinou PP, Boletis JN, Skopouli FN, et al. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology. 2004;43:377-380. (Pubitemid 38313191)
15. Kasitanon N, Petri M, Haas M, et al. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases. Lupus. 2008;17:40-45. (Pubitemid 351487018)
16. Kitiyakara C, Ophascharoensuk V, Changsirikulchai S, et al. Treatment of lupus nephritis and primary glomerulonephritis with enteric-coated mycophenolate sodium. Clin Nephrol. 2008;69:90-101. (Pubitemid 351227961)
17. Lau KK, Jones DP, Hastings MC, et al. Short-term outcomes of severe lupus nephritis in a cohort of predominantly African-American children. Pediatr Nephrol. 2006;21:655-662.
18. Mak SK, Lo KY, Lo MW, et al. Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis. Nephrology. 2008;13:331-336.
19. Mok CC, Ying KY, Lau CS, et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis. 2004;43:269-276. (Pubitemid 38146325)
20. Moroni G, Maccario M, Banfi G, et al. Treatment of membranous lupus nephritis. Am J Kidney Dis. 1998;31:681-686. (Pubitemid 28158010)
21. Nathanson S, Salomon R, Ranchin B, et al. Prognosis of lupus membranous nephropathy in children. Pediatr Nephrol. 2006;21: 1113Y1116. (Pubitemid 44083883)
22. Rivera TL, Belmont HM, Malani S, et al. Current therapies for lupus nephritis in an ethnically heterogeneous cohort. J Rheumatol. 2009;36:298Y305.
23. Spetie DN, Tang Y, Rovin BH, et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int. 2004;66:2411-2415.
24. Szeto CC, Kwan BC, Lai FM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology. 2008;47:1678-1681.
25. Tam LS, Li EK, Szeto CC, et al. Treatment of membranous lupus nephritis with prednisone, azathioprine and cyclosporin A. Lupus. 2001;10:827-829. (Pubitemid 34007900)
26. Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77:152-160.
27. Wong SS, Chan WK, Jui J, et al. Membranous lupus nephritis in Chinese childrenVa case series and review of the literature. Pediatr Nephrol. 2009;10:1989-1996.
28. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103Y1112.
29. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971-980. (Pubitemid 38269274)
30. Donadio JV Jr, Burgess JH, Holley KE. Membranous lupus nephropathy: a clinicopathologic study. Medicine. 1977;56:527Y536. (Pubitemid 8229841)
31. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219-2228. (Pubitemid 41697285)
32. Gonzalez-Dettoni H, Tron F. Membranous glomerulopathy in systemic lupus erythematosus. Adv Nephrol. 1984;14:347-364.
33. Hallegua D, Wallace DJ, Metzger AL, et al. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus. 2000;9:241-251. (Pubitemid 30261065)
34. Radhakrishnan J, Kunis CL, D'Agati V, et al. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol. 1994;42:147-154. (Pubitemid 24287748)
35. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277. (Pubitemid 13221242)
36. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241-250. (Pubitemid 38140764)
37. Mok CC, Ying KY, Yim CW, et al. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus. 2009;18:1091-1095.